AIM OF STUDY: This study was undertaken to elucidate the anti-obesity mechanism of a new purple potato variety that has been used for the prevention of metabolic diseases as a folk remedy in Korea. MATERIALS AND METHODS: Proliferation assay, differentiation assay, Western blotting, were performed in 3T3-L1 adipocytes, while blood chemistry for hyperlipidemic parameters, measurement of body weight and abdominal fats, reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, magnetic resonance image (MRI) scanning were carried out in high fat diet fed Sprague-Dawley rats with ethanol extract of Solanum tuberosum L. cv. Bora Valley (ESTBV). RESULTS: ESTBV significantly inhibited the proliferation and differentiation of 3T3-L1 cells as well as reduced the cellular leptin level. ESTBV also significantly attenuated the levels of insulin and leptin at 500mg/kg in high fat diet fed rats. In addition, ESTBV significantly reduced total fat and whole body lipid in a therapeutic experiment, which was confirmed by MRI scanning and also significantly inhibited the retroperitoneal and epididymal fats in a preventive experiment compared with control. Similarly, the levels of total cholesterol, triglyceride and low density lipoprotein (LDL) were significantly reduced at a lower dose 200mg/kg of ESTBV in a preventive experiment than at 500mg/kg in a therapeutic experiment. Furthermore, body weight gain was significantly suppressed by over 4 weeks treatment of ESTBV compared with control. Interestingly, the expression of p38 mitogen-activated protein kinase (MAPK) was significantly downregulated in 3T3-L1 cells by ESTBV and the expression of uncoupled protein 3 (UCP-3) was activated in fats and liver tissues of ESTBV treated group compared with high fat diet control. CONCLUSION: ESTBV has anti-obesity potential via inhibition of lipid metabolism through p38 MAPK and UCP-3 pathways.
AIM OF STUDY: This study was undertaken to elucidate the anti-obesity mechanism of a new purple potato variety that has been used for the prevention of metabolic diseases as a folk remedy in Korea. MATERIALS AND METHODS: Proliferation assay, differentiation assay, Western blotting, were performed in 3T3-L1 adipocytes, while blood chemistry for hyperlipidemic parameters, measurement of body weight and abdominal fats, reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, magnetic resonance image (MRI) scanning were carried out in high fat diet fed Sprague-Dawley rats with ethanol extract of Solanum tuberosum L. cv. Bora Valley (ESTBV). RESULTS: ESTBV significantly inhibited the proliferation and differentiation of 3T3-L1 cells as well as reduced the cellular leptin level. ESTBV also significantly attenuated the levels of insulin and leptin at 500mg/kg in high fat diet fed rats. In addition, ESTBV significantly reduced total fat and whole body lipid in a therapeutic experiment, which was confirmed by MRI scanning and also significantly inhibited the retroperitoneal and epididymal fats in a preventive experiment compared with control. Similarly, the levels of total cholesterol, triglyceride and low density lipoprotein (LDL) were significantly reduced at a lower dose 200mg/kg of ESTBV in a preventive experiment than at 500mg/kg in a therapeutic experiment. Furthermore, body weight gain was significantly suppressed by over 4 weeks treatment of ESTBV compared with control. Interestingly, the expression of p38 mitogen-activated protein kinase (MAPK) was significantly downregulated in 3T3-L1 cells by ESTBV and the expression of uncoupled protein 3 (UCP-3) was activated in fats and liver tissues of ESTBV treated group compared with high fat diet control. CONCLUSION: ESTBV has anti-obesity potential via inhibition of lipid metabolism through p38 MAPK and UCP-3 pathways.
Authors: Jan Martel; David M Ojcius; Chih-Jung Chang; Chuan-Sheng Lin; Chia-Chen Lu; Yun-Fei Ko; Shun-Fu Tseng; Hsin-Chih Lai; John D Young Journal: Nat Rev Endocrinol Date: 2016-09-16 Impact factor: 43.330
Authors: Heeok Hong; Joseph F Dela Cruz; Won Seob Kim; Kiyeol Yoo; Seong Gu Hwang Journal: Evid Based Complement Alternat Med Date: 2018-04-18 Impact factor: 2.629